Kailera Therapeutics, Inc. (KLRA) Financial Statements

52 Followers

Kailera Therapeutics, Inc. Financial Overview

Kailera Therapeutics, Inc.'s market cap is currently $2.10B. The company's EPS TTM is $-1.76; its P/E ratio is -9.22; Kailera Therapeutics, Inc. is scheduled to report earnings on August 12, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25
Income Statement
Total Revenue	$ 0.00
Gross Profit	$ 0.00
Operating Income	$ -158.34M
EBITDA	$ -158.03M
Net Income	$ -148.96M
Balance Sheet
Cash & Short-Term Investments	$ 546.06M
Total Assets	$ 692.29M
Total Debt	$ 10.75M
Net Debt	$ -149.51M
Total Liabilities	$ 1.05B
Stockholders' Equity	$ -356.46M
Cash Flow
Free Cash Flow	$ -122.30M
Operating Cash Flow	$ -120.21M
Investing Cash Flow	$ -492.60M
Financing Cash Flow	$ 598.66M

Currency in USD

Kailera Therapeutics, Inc. Earnings and Revenue History

Income Statement >

Kailera Therapeutics, Inc. Debt to Assets

Balance Sheet >

Kailera Therapeutics, Inc. Cash Flow

Cash Flow >

Kailera Therapeutics, Inc. Forecast EPS vs Actual EPS

Earnings >